Suraksha Diagnostic Limited — Investor Meet, 14-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Suraksha Diagnostic Limited reported total income of INR 601.1 crore for Q3 FY25, marking a year-on-year growth of 14.1%. The nine-month revenue stands at INR 1,900.3 crore, up 14.4% from the previous year. Despite the growth, Q3 profitability faced headwinds due to seasonal factors and a doctors' strike, leading to a Q3 profit after tax of INR 59.8 crore, which is a 31.9% increase year-on-year. The EBITDA for the quarter reached INR 188.6 crore, with a margin of 31.7%, showing a modest improvement from last year.

2. **Future Outlook and Growth Drivers**: Management emphasized the potential for significant growth in the diagnostics sector, specifically in the East of India, which remains underpenetrated. Plans include adding 12 to 15 new centers annually, with a strategic focus on expanding both organically and through potential acquisitions that align with their growth objectives.

3. **Order Book and Operational Updates**: The company currently operates 53 diagnostic centers and plans to add six more by March 2025. In the past nine months, Suraksha served 0.9 million patients and conducted approximately 4.87 million tests, underscoring the steady demand despite external challenges.

4. **Analyst Q&A Insights (Detailed)**: Analyst inquiries highlighted the revenue loss due to the doctors’ strike, estimated at INR 10 to 12 crore. Management clarified that while seasonality affects revenue, margins were also pressured due to fixed costs outpacing revenue growth. On operational challenges, they noted the doctors' strike has now subsided, though patient inflow from Bangladesh remains below normal levels but is on an upward trend. Analysts also probed capital expenditures, with management indicating a focus on maintenance spending being around 5-7% of their annual INR 70 crore capex budget.

5. **Market or Regulatory Updates**: No significant regulatory changes were noted, but management acknowledged increased competition in Eastern India, although they believe the market holds ample opportunity given low penetration rates.

6. **Strategic Focus Areas**: The focus remains on technological advancements and operational efficiency, with management noting their leadership in high-end diagnostic services like genomics and super-specialties as competitive advantages. The establishment of a significant genomics platform is a key component of their future growth strategy.

7. **Investor Insight**: The company’s solid revenue growth and proactive strategies to expand its diagnostic network and services position it favorably for future gains. The resilience displayed during challenging quarters suggests a buy case, especially as previous disruptions are acknowledged to be temporary, signaling potential recovery and growth. The sustainable margin expansion outlook also adds to a positive investment sentiment.